181 results about "Drug release rate" patented technology

The invention provides a sleep-aiding medicine pillow dynamic regulation and control method and system based on physiological parameter analysis. According to the method, pressure data and sleep bio-electricity signals of a contact area of a user are collected in real time, a characteristic frequency band proportion and a heart rate fluctuation parameter are analyzed, and a correlation model is established; calculating a bioelectricity signal energy integral value of the characteristic frequency band based on the model, and quantizing to generate a bioelectricity intensity index; the heat conduction efficiency is changed by adjusting the molecular density of the temperature-sensitive material, and a contact layer heat transfer dynamic instruction is generated; pressure feedback and instruction waveform characteristics are combined, the micropore on-off duty cycle is adjusted, and the opening duration of unit time is controlled; the drug release rate is synchronously adjusted, so that the response waveform and the heat conduction instruction are dynamically balanced, and closed-loop regulation is formed. According to the application, through multi-parameter dynamic analysis and feedback adjustment, accurate cooperative control of heat conduction and medicine release of the medicine pillow is realized, and the matching degree of sleep-aiding substance release and sleep rhythm is optimized.

The invention belongs to the technical field of medicine preparation, and relates to PLGA gel used as an injectable long-acting local anesthesia medicine as well as application and a preparation method of the PLGA gel. The PLGA gel comprises the PLGA gel which is loaded with superparamagnetic Fe3O4 particles and a small molecule local anesthetic, namely, levobupivacaine (Levobupi). The PLGA hydrogel containing Fe3O4 and levobupivacaine can be used as an injectable long-acting local anesthesia medicine, and the hydrogel can be changed from liquid to solid after being injected into a living body, so that the release efficiency of the medicine is slowed down, and the local action time of the hydrogel is prolonged. In addition, the hydrogel can undergo a phase change from a solid state to a liquid state under magnetocaloric therapy (MHT), increase pore diameter, promote release of levobupivacaine, and provide enhanced pain relief in vivo. Compared with the prior art, the invention has the beneficial effects of simple synthesis and easy industrialization. The drug release rate is adjusted through the phase change of the hydrogel, super-long-acting analgesia is realized, and the analgesia time is gt; 20 days. The gel can be loaded with various local anesthesia drugs such as L-bupivacaine, and pain management can be carried out on various pain scenes clinically.

The invention relates to a composite hydroxypropyl methylcellulose skeleton sustained-release material and a preparation method thereof, and belongs to the technical field of drug sustained release. The sustained-release material is prepared from 70 to 90 parts of hydroxypropyl methylcellulose (HPMC), 10 to 20 parts of sodium alginate, 8 to 15 parts of chitosan, 0.1 to 0.2 part of Omega-3 fatty acid, 0.05 to 0.06 part of vitamin D, 2.5 to 5 parts of soluble calcium salt-zinc salt composite cross-linking agent, 0.5 to 1.5 parts of hydrolyzable cross-linking agent, 3 to 10 parts of enzyme sensitive auxiliary material, 1 to 5 parts of pore-foaming agent and 2 to 8 parts of hydrophobic blocking agent. The preparation method comprises the steps of raw material pretreatment and dry mixing, active component dispersion liquid preparation, wet granulation and primary cross-linking, secondary cross-linking and drying, vacuum drying and size stabilization, curing and packaging and the like. The sustained-release material provided by the invention has the advantages of controllable drug release rate, good mechanical strength and biodegradability, is suitable for sustained-release delivery of Omega-3 fatty acid, vitamin D and other active components, and can improve the bioavailability and stability of drugs.

The invention relates to the technical field of medicines, in particular to a dihydroergoline mesylate controlled release tablet and a preparation method thereof. The dihydroergoline mesylate controlled release tablet comprises a tablet core, an inner coating and an outer coating, wherein the tablet core is coated with the inner coating and the outer coating layer by layer; the weight ratio of the tablet core to the inner coating to the outer coating is 50: (6-8): (3-5); the dihydroergoline mesylate tablet solves the problem that the drug release rate of the existing dihydroergoline mesylate tablet is unstable, and realizes more uniform and predictable drug release characteristics. By optimizing preparation components and a preparation process, the controlled-release tablet disclosed by the invention can maintain stable drug concentration in vivo, and the treatment experience of a patient is improved.

The invention provides a thermo-sensitive block polymer as well as a preparation method and application thereof. The temperature-sensitive block polymer comprises a temperature-sensitive unit, a hydrophilic unit and a pH response unit, the number-average molecular weight of the thermo-sensitive block polymer is 1 * 10 < 3 > g / mol to 2.5 * 10 < 5 > g / mol, preferably 8 * 10 < 3 > g / mol to 2.0 * 10 < 4 > g / mol; molecular weight distribution lt; 1.50, preferably < 1.30. The preparation method comprises the following steps: mixing an RAFT reagent, an initiator, a hydrophilic polymer or a hydrophilic monomer, a temperature-sensitive monomer, a pH response monomer and a solvent, carrying out an active free radical polymerization reaction in a protective gas atmosphere, and carrying out post-treatment on a product to obtain the temperature-sensitive block polymer. The obtained thermo-sensitive block polymer is narrow in molecular weight distribution, the drug release rate is more controllable, and the drug effect is improved.

The invention relates to the technical field of adjuvant therapy monitoring, in particular to an anorectal disease adjuvant therapy monitoring system and method based on a radix scrophulariae extract. The method comprises two stages of system initialization and adjuvant therapy monitoring, in the initialization stage, initialization setting is completed, and a dynamic monitoring code is generated to guarantee data transmission security; in the auxiliary treatment stage, baseline data are collected, abnormal values are removed, then personalized baselines are generated, the drug dosage and the release rate are adjusted according to the baseline data, meanwhile, pressure, temperature, blood flow and electrophysiological data are monitored in real time, key indexes are calculated, monitoring labels are generated, the physiological indexes are standardized, the treatment effect is comprehensively evaluated, and classification is conducted. The dynamic trend is analyzed by adopting a polynomial fitting method, an evaluation result is generated, the drug release rate and dosage are dynamically optimized in combination with real-time monitoring data and patient feedback, and fine treatment is further performed by adopting a feedback adjustment mechanism. According to the invention, efficient auxiliary treatment and intelligent monitoring of anorectal diseases are realized.

The invention discloses a nanometer material-based postoperative wound intelligent healing patch preparation method, which comprises: S1, preparing a temperature response layer, and compounding PNIPAM with surface-modified zinc oxide nanoparticles; s2, preparing a pH response layer, and compounding chitosan with the surface modified titanium dioxide nanoparticles; s3, a humidity response layer is prepared, and release of silver ions is optimized by adopting a PEGDA and silver nanoparticle composite material; s4, assembling the layers layer by layer through an electrostatic spinning technology or a lamination technology, and controlling process parameters in combination with meta learning and transfer learning to complete preparation of an overall structure of the patch; s5, embedding temperature, pH and humidity sensors, and constructing a sensor data set; s6, the drug release rate and the material phase change behavior are dynamically adjusted, and accurate response is achieved; and S7, after patch preparation is completed, combining Bayes and a multi-objective evolutionary algorithm to optimize sterilization parameters. The intelligent healing patch is prepared by combining a nano material with an intelligent algorithm, and real-time environmental response is realized.

The invention relates to the technical field of medical gel, in particular to gynecological vaginal mucosa repairing gel and a preparation method thereof. Comprising the following raw materials: carbomer, glycerol, sodium hyaluronate, vitamin E, potassium sorbate, a modified nano polylactic acid-glycolic acid copolymer, modified nano collagen, albumin, tea tree essential oil, aloe, astragalus membranaceus, dandelion, stigma croci and ginseng. The modified nano polylactic acid-glycolic acid copolymer, the modified nano collagen and the albumin play a role through a synergistic effect, and the modified nano polylactic acid-glycolic acid is used as a skeleton structure for cell growth and is firmly attached to the active pharmaceutical ingredient-albumin compound; the polyacrylic acid chain on the surface controls the drug release rate by sensing the change of the pH value, the albumin initiates endocytosis through specific binding, and the albumin and the modified nano collagen jointly improve the anti-inflammatory performance, promote cell proliferation and differentiation and promote repair and regeneration of vaginal mucosa tissues.

The invention relates to the technical field of drug release control. By providing a multi-modal data fusion nano-drug release kinetics prediction method, device and equipment and a medium, the method comprises the following steps: acquiring permeation path image data of a nano-drug in a target tissue, and acquiring drug release rate chemical data; performing time dimension synchronization processing on the permeation path image data and the drug release rate chemical data to generate a multi-modal space-time correlation data set; performing feature extraction processing on the multi-modal time-space correlation data set to obtain nano-drug permeation behavior features and release dynamics fluctuation features; constructing a space-time diagram neural network prediction model; training the space-time diagram neural network prediction model to obtain a trained prediction model; and generating a personalized drug release scheme through a reverse optimization algorithm on the basis of the drug release kinetics prediction curve and the quantitative index of the degree of variability, so as to achieve the technical effects of improving the prediction precision, enhancing the model adaptability and reducing the curative effect volatility.

The invention discloses a sustained-release pill as well as a preparation method and application thereof, and belongs to the technical field of medicines. The sustained-release pill comprises a pill core and a coating layer coated outside the pill core, the pellet core is prepared from the following raw materials in parts by mass: 8 to 14 parts of loxoprofen sodium, 30 to 60 parts of a filling agent, 3 to 10 parts of an adhesive, 2 to 10 parts of a disintegrating agent, 0.1 to 2 parts of a penetration enhancer, 0.05 to 0.2 part of a pH regulator, 0.1 to 0.5 part of a surfactant and 0 to 20 parts of an auxiliary agent; the coating layer is prepared from an aqueous dispersion liquid containing acrylic resin; the coating layer is prepared from an aqueous dispersion liquid containing acrylic resin. Aiming at the drug characteristics of loxoprofen sodium, the loxoprofen sodium sustained-release tablet is composed of specific auxiliary materials, the drug composition is optimized, the drug release rate is accurately controlled, the bioavailability and stability of the drug are effectively improved, and the loxoprofen sodium sustained-release tablet has a good application prospect in preparation of antipyretic and analgesic drugs.

The invention relates to the technical field of drug delivery systems. The invention provides an osmotic pump drug release system based on a fenerenone solid dispersion and a preparation method of the osmotic pump drug release system. According to the fenerenone solid dispersion prepared by adopting a hot melt extrusion technology and the osmotic pump drug release system based on the fenerenone solid dispersion, the solubility and the bioavailability of the fenerenone in the solid dispersion can be improved, and drug absorption can be accelerated; the sustained and stable release of the fenerenone can be realized, the drug release rate is optimized, the effectiveness and safety of the drug in the treatment process are ensured, the chemical stability of the fenerenone is improved, and the validity period of the drug is prolonged. Various challenges of the fenerenone in the using process are effectively solved, a more effective and safer treatment scheme is provided for patients suffering from chronic kidney diseases complicated with type 2 diabetes, and important practical value and wide market prospects are achieved.

The invention discloses diosmetin temperature-sensitive liposome and a preparation method thereof, the diosmetin temperature-sensitive liposome is prepared by adopting a film hydration method, and dipalmitoyl phosphatidylcholine and 1-myristoyl-2-stearoyl phosphatidylcholine are combined through hydrogen bonds and hydrophobic force to form a stable liposome structure. The dipalmitoyl phosphatidylcholine provides a basic phospholipid double-layer structure, the 1-myristoyl-2-stearoyl phosphatidylcholine enables the liposome to have a structural change at a specific temperature, so that the fluidity and the structure of a liposome membrane are changed, the thermo-sensitive liposome is formed, the diosmetin is encapsulated in a hydrophobic cavity of the thermo-sensitive liposome, and the stability of the diosmetin is improved. According to the diosmetin temperature-sensitive liposome, active ingredients are protected, the bioavailability of the diosmetin temperature-sensitive liposome is improved, remarkable drug release can be achieved at the target temperature, accurate control over the drug release rate is achieved, the treatment effect is enhanced, and side effects are reduced.

In this specification, a new design and formulation of an expandable, gastroretentive fibrous dosage form is presented where the post-expansion mechanical strength and the drug release rate can be independently controlled. The dosage form generally comprises a fluid-absorptive, three-dimensional structural network of one or more fibers, a mechanically strengthening semi-permeable layer substantially encapsulating said fiber network, and a drug-containing solid attached to said encapsulated network.

The invention discloses a hydrogel microsphere system for sequential delivery of drugs as well as a preparation method and application thereof, and particularly relates to the technical field of biomedical materials. The microsphere system comprises inflammation responsive hydrogel microspheres obtained by grafting molecules containing inflammation responsive groups with hyaluronic acid as a skeleton, common microspheres obtained by grafting non-responsive molecules with hyaluronic acid as a skeleton, an anti-inflammatory drug and a healing promoting drug. Wherein the molecular weight of the hyaluronic acid is 74-800kDa, the inflammation responsive hydrogel microspheres are loaded with anti-inflammatory drugs, and the common microspheres are loaded with healing promoting drugs. According to the hydrogel microsphere system, the drug release rate and degradation time of the microspheres are adjusted by limiting the molecular weight of hyaluronic acid, and a molecular basis is provided for subsequent differentiated drug release.

The invention relates to the technical field of alimentary canal diagnosis and treatment, in particular to an alimentary canal detection drug delivery system which comprises an alimentary canal sensing unit for collecting an image, a pH value, a temperature and pathological tissue pathological characteristic data in an alimentary canal cavity; the lesion positioning analysis unit identifies a lesion area through an image segmentation algorithm, constructs a lesion three-dimensional coordinate model according to physiological parameters, prejudges a lesion displacement trend in combination with an alimentary canal peristalsis rule, analyzes a lesion state in stages, and outputs lesion severity; the response type drug delivery module controls the micro drug delivery device to perform targeted release and adjust the drug release rate based on the lesion coordinates and the intracavity environment parameters; the data collaboration platform shares a detection result and a drug administration record through a real-time interaction interface; the curative effect feedback unit is used for collecting physiological index change and patient symptom improvement data after drug administration, judging the drug onset period and possible adverse reactions, and optimizing drug administration parameters and detection frequency. Therefore, the problems of low targeting precision, poor diagnosis and treatment efficiency and the like in the prior art are solved.

The invention relates to the technical field of medical instruments, in particular to an intravascular stent. According to the specific technical scheme, the intravascular stent comprises a stent skeleton, after the stent skeleton is subjected to surface treatment, at least one layer of film covering section is arranged outside the stent skeleton, and medicine release sections are arranged at the two ends of the stent skeleton. The problems that in the drug release process of an existing stent, the drug release rate is uneven, biocompatibility is poor, and thrombus and restenosis are caused by a metal stent are solved.

The embodiment of the invention provides an emergency clinical data real-time sharing method and system based on the Internet of Things. Wherein the biological parameters of the wound part are monitored in real time by using the intelligent dressing integrated with the antibacterial coating, and the data are transmitted to the emergency clinical data collaboration platform through the low-power wide area network. According to the relationship between the aperture of the antibacterial coating and the drug release rate, an optimal drug release curve is screened out. In combination with cross-mechanism wound infection historical data, federal learning is adopted to construct an infection risk evolution model, and infection risk quantitative parameters are generated. The data are comprehensively analyzed, the drug release rate and the effective time window are dynamically adjusted, and the abnormal correlation threshold value is corrected. And based on the analysis result, automatically generating a wound infection early warning instruction and an emergency treatment data sharing instruction so as to assist in clinical decision making. According to the technical scheme provided by the embodiment of the invention, the efficiency and accuracy of real-time sharing of emergency clinical data can be improved.

The invention belongs to the technical field of medical treatment, and particularly relates to an analgesic anti-inflammatory drainage tube which comprises an outer tube, an inner tube and a medicine guide tube, the inner tube is arranged in the outer tube, connected with a first one-way valve and connected with the medicine guide tube through the first one-way valve, and the medicine guide tube is connected with a medicine slow release device; the medicine slow-release device comprises a slow-release cavity, a suction pump, a partition plate and a pressing mechanism, a medicine guiding cavity is fixed in the slow-release cavity and connected with a medicine guiding pipe, the partition plate is fixedly installed on the inner wall of the slow-release cavity, a through hole is formed in the middle of the partition plate, an injection pipe is connected to the right side of the bottom of the slow-release cavity, and a second one-way valve is arranged in the injection pipe. The device solves the problems that when a current drainage tube releases a medicament, the medicament release speed and the single release amount cannot be accurately adjusted, so that the medicament supply is too much or insufficient, and manual control and automatic control cannot be freely selected, so that the surgical risk is increased.

The invention discloses a device and method for using a brain malignant tumor operation cavity preset omaya capsule for postoperative chemotherapy, relates to the field of medical treatment, and solves the problem that a preset omaya capsule chemotherapy method is poor in treatment effect, and the device comprises a data acquisition module which is used for acquiring a patient medical record, a sample preset medicine, a first medicine decomposition weight and a second medicine decomposition weight, the system comprises a data acquisition module used for acquiring patient condition monitoring data, a data analysis module used for analyzing the patient condition monitoring data and acquiring a release rate of a sample preset drug to obtain an actual drug release rate, and a drug release module used for monitoring a drug release process to obtain a first drug release monitoring coefficient and a second drug release monitoring coefficient, the release evaluation module is used for carrying out release operation evaluation on the preset medicine of the sample according to the medicine release monitoring data, and the treatment effect of the preset omaya capsule chemotherapy method can be further improved.

The application discloses a mouse wearable micro-injection device for slow release of rhodiolin, and relates to the technical field of medical miniaturized devices. The device comprises a fixing frame, a slow injection device arranged at the upper end of the fixing frame, and a flow guide device connected with the slow injection device. The slow injection device comprises a syringe body internally provided with a liquid storage area and a reaction area. An injection plug is arranged between the liquid storage area and the reaction area. The side edge of the injection plug is in close contact with the inner wall of the syringe body. The flow guide device is in communication with the liquid storage area. The device can realize accurate control of the drug release rate through three different reaction mechanisms, i.e. gas driving of a drug bin, physical expansion of an expansion bag and composite expansion of an expansion bin. In addition, the design of the hanging ear port in the fixing frame can not only disperse the pressure on the ears, but also reduce the fluctuation range of the mouse's corticosterone level in combination with the lightweight structure design.

The invention discloses a kinesio bandage with a slow release function and a preparation process thereof, the kinesio bandage comprises a functional spraying agent, and a contact layer, a slow release layer and a substrate layer which are laminated and compounded in sequence, and the invention relates to the technical field of kinesio. According to the kinesio bandage with the slow release function and the preparation process thereof, a functional spraying agent is independently designed, when the kinesio bandage is used, coupling of the functional spraying agent and a buffer layer is achieved by spraying the functional spraying agent to a contact layer, and under the moisture absorption effect of sodium polyacrylate moisture absorption particles, rapid gelation of the functional spraying agent on the surface of the contact layer is achieved; according to the present invention, the skin surface temperature is responded through the poloxamer 407, such that the rapid formation of the gel state of the contact layer is ensured, the drug release speed is accelerated along with the increase of the skin surface temperature, and the dynamic drug sustained release support condition is provided for the sports personnel;

The microwave controlled-release corrosion type microneedle emplastrum comprises corrosion type microneedles, emplastrum, a microwave device, a power supply device, a regulation and control device and a fixing device, medicine is carried in the emplastrum, the corrosion type microneedles are arranged in a matrix mode and embedded in an emplastrum body layer, the emplastrum does not contain percutaneous absorption enhancer, and the microwave device is connected with the microwave device. The arrangement sequence of the corrosion type microneedle, the emplastrum and the microwave device is as follows: the corrosion type microneedle, the emplastrum and the microwave device. The microwave controlled-release corrosion type microneedle emplastrum is applied to the skin surface and organically combines a microwave mediation technology, an emplastrum, a corrosion type microneedle technology and an intelligent controlled-release technology to form a synergistic complementary effect; the problems that a traditional skin preparation is difficult to penetrate through a skin barrier, the drug release rate cannot be accurately controlled, and the dosage cannot be adjusted in time are solved, and transdermal drug absorption is facilitated to achieve the treatment effect to achieve safe and intelligent treatment.

The invention relates to the technical field of medicines, in particular to a budesonide-loaded oral colon targeting delivery system, a preparation method and application. According to the delivery system, budesonide entrapped by Pickering emulsion serves as a core, and a low-ester pectin-calcium ion cross-linked inner layer and a low-ester pectin-chitosan polyelectrolyte composite outer layer are sequentially wrapped on the outer layer; the preparation process is realized by combining an emulsion template method with a layer-by-layer self-assembly technology, the obtained microcapsule is of a uniform spherical structure, the particle size is about 400 microns, and the microcapsule has a double-layer three-dimensional network structure. The delivery system is kept stable in the gastrointestinal environment and releases drugs rapidly only under the colon pH condition, in-vitro simulation experiments show that the drug release rate in the stomach / small intestine stage is lower than 5%, and the drugs are released rapidly in the colon stage. Animal experiments prove that the effect of treating ulcerative colitis is equivalent to that of mesalazine, the toxicity of the whole body is remarkably reduced, the residence time of the medicine at the colon part exceeds 24 hours, and the medicine is not accumulated in a non-target organ.

The present invention relates to a coating material for drug-coated balloons, drug-coated balloons, and a coating solution for drug-coated balloons, as well as their preparation and application. The coating solution comprises an aqueous solvent and a plurality of core-shell structures dispersed in the aqueous solvent, each of which comprises a lipid bilayer coated with a drug. The core of the core-shell structure contains a plurality of drug-loaded particles, and the shell of the core-shell structure is a lipid bilayer with an outer hydrophilic group and an inner hydrophobic group. The drug-loaded particles comprise a plurality of drug-loaded nanocrystalline particles. The combination of nanocrystals and liposomes combines the advantages of these two types of drug carriers. The resulting lipid bilayer improves the solubility of poorly soluble drugs in drug-coated balloons, resulting in a high drug loading capacity, high drug carrier stability, and stable drug crystal form, allowing for controllable drug release rates.

The invention discloses a preparation method and application of a hyaluronic acid-glycyrrhetinic acid and hyaluronic acid-ferulic acid conjugate nanoparticle drug delivery system, and relates to the technical field of biological pharmacy. The key points of the technical scheme are as follows: GA and FA are respectively connected with HA by using adipic acid dihydrazide as a connexon; and the hyaluronic acid-glycyrrhetinic acid and hyaluronic acid-ferulic acid polymer prodrugs are synthesized. An in-vitro release result shows that when the NPs are exposed in a physiological medium with slightly acidic pH, the drug release rate is higher than that in a blood environment with pH of 7.4. And the drug release rate and the drug release amount of the nanoparticles are superior to those of single drug release. The HA-ADH-GA and the HA-ADH-FANPs both have relatively low toxicity in vitro and a good effect of resisting the influenza A virus H1N1. Compared with the HA-ADH-FANPs, the HA-ADH-GANPs has the advantage that the HA-ADH-GANPs has a better protection effect on a mouse infected with the H1N1-UI182 in vivo.

The present invention relates to a multiple controlled-release tablet composition of ruxolitinib or a pharmaceutically acceptable salt thereof, which is useful for treating Janus kinase-associated diseases such as myeloproliferative disorders, and a method for producing the same. More specifically, the present invention relates to a multiple controlled-release tablet composition and a method for producing the same, which exhibits a maximum drug blood concentration similar to that of commercially available immediate-release formulations, while controlling the drug release rate so as to efficiently maintain the drug at or above the effective blood concentration in the body, thereby enabling once-daily administration, unlike commercially available formulations that are administered twice daily.

The present invention relates to a prodrug and drug having a controllable drug release rate. Specifically provided are a prodrug or a stereoisomer, deuterated substance, solvate, polymorph or pharmaceutically acceptable salt thereof. The prodrug contains a drug and a linker, wherein the drug is linked to the linker, and the linker contains a structure as represented by formula (1). The prodrug has a long half-life, does not require an enzymatic or redox environment, can controllably and spontaneously release the drug under physiological conditions, and exhibits a high drug delivery efficiency. The released drug exhibits a complete activity and is not affected by the linker or a macromolecular carrier.

The invention discloses an internal jugular vein semi-permanent catheter with a self-adaptive epidermal growth factor release mechanism, and belongs to the technical field of medical instruments. The catheter comprises a catheter body and a multifunctional medicine release covering film arranged at the telecentric end in a covering mode, the covering film is made of biocompatible polymers, epidermal growth factors (EGF) and antibacterial agents are loaded on the covering film in a gradient mode, and a micro sensor is arranged in the covering film. The sensor is linked with an intelligent feedback system, the drug release rate can be dynamically adjusted according to local physiological conditions, and meanwhile wireless data transmission and remote monitoring are supported. The defects of an existing semi-permanent catheter in the aspects of infection prevention, healing promotion and dynamic adjustment are overcome, targeted drug release, continuous antibiosis, self-adaptive feedback and remote management are achieved, and the long-term implantation requirement is met.

The invention belongs to the technical field of medicines, and particularly relates to an implant for sustained-release drug delivery, a preparation method of the implant and an eye drug. Wherein the implant comprises a drug-loading matrix and active drugs discretely distributed in the drug-loading matrix, the drug-loading matrix comprises a degradable polymer, and mass transfer ducts of the active drugs are arranged in the drug-loading matrix and on the surface of the drug-loading matrix. According to the implant for sustained-release drug delivery, an active drug mass transfer pore channel is established, so that an active drug can be timely subjected to mass transfer and release, and meanwhile, the mass transfer pore channel can be used for timely exporting a degradation product of the drug, so that the degradation speed of the drug is controlled, drug burst release caused by an autocatalytic reaction in the degradation process of a degradable polymer is reduced, and the drug release rate is increased. The treatment effect is favorably improved.

The invention discloses a drug balloon and a preparation method thereof.The drug balloon prepared through the method comprises a catheter, a balloon body and a coating, a sunken drug storage part is arranged on the surface of the balloon body, the section of the bottom of the drug storage part is in an inverted triangle shape, and when the balloon body is in a full state, the drug storage part is changed into a protruding part from a sunken part, and the section of the top of the drug storage part is in a regular triangle shape. The medicine storage part can be coated with the medicine through precise printing, the medicine in the medicine storage part is protected by the fat-soluble medicine on the outer layer, the influence of blood flow flushing on the medicine coating is reduced, the loss of the medicine coating during conveying is reduced, and the transfer rate of the medicine coating is increased. According to the structure of the medicine storage part, on the premise that the outer diameter is not increased, the surface area of the balloon is increased, the medicine loading capacity is improved, the trafficability of the balloon is not affected, when the medicine balloon is in a full state, the medicine storage part is changed from a concave part to a convex part, the convex tip can break stubborn calcified thrombus, the medicine release rate and hemodynamics are improved, and the medicine is rapidly released and directly reaches lesion.